Low dosage methotrexate (NSC-740) and cyclophosphamide (NSC 26271) for solid tumors.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007822:Laryngeal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy; D008175:Lung Neoplasms / Q000000981:diagnostic imaging; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D011859:Radiography; D012004:Rectal Neoplasms / Q000188:drug therapy; D013280:Stomatitis / Q000139:chemically induced; D009396:Wilms Tumor / Q000188:drug therapy
D004338:Drug Combinations; D003520:Cyclophosphamide; D008727:Methotrexate